{
 "title": "GLP-1 'microdosing': ClinicalTrials.gov hand review, label dosing scan and PubMed count",
 "built": "2026-10-20",
 "publisher": "Jabbit (jabbitapp.com)",
 "method": "ClinicalTrials.gov API v2 pulled 2026-10-20 04:09 ET: every study listing semaglutide, tirzepatide or liraglutide as an intervention plus free-text pulls pairing GLP-1 names with microdose, low-dose, taper, interval and maintenance-dose words (1708 unique records). 240 records used dose-lowering language in title, summary, arms or interventions; each was read by hand. Kept: studies that deliberately give a GLP-1 drug below its usual dose or schedule (named microdosing, longer intervals, click dosing, step-down or taper, or a fixed 'low dose'). Dropped: normal escalation schedules, permission to lower a dose for side effects, and low doses of other drugs. SURMOUNT-MAINTAIN was added by hand because its registry text does not use dose-lowering words.",
 "query_counts": {
  "intr:semaglutide": 788,
  "intr:tirzepatide": 303,
  "intr:liraglutide": 515,
  "term1": 5,
  "term2": 154,
  "term3": 21,
  "term4": 116,
  "term5": 157
 },
 "kept": 15,
 "kept_results_posted": 0,
 "by_category": {
  "named microdosing": 3,
  "extended interval": 1,
  "click-based titration": 1,
  "step-down maintenance": 1,
  "taper to stop": 3,
  "taper": 1,
  "fixed low dose": 5
 },
 "trials": [
  {
   "nct": "NCT07092605",
   "title": "Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures",
   "sponsor": "AgelessRx",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "EARLY_PHASE1"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 150,
   "enrollment_type": "ESTIMATED",
   "status": "ENROLLING_BY_INVITATION",
   "start": "2024-11-01",
   "primary_completion": "2025-11-01",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2025-07-30",
   "last_update": "2025-07-30",
   "results_posted": false,
   "primary_outcomes": [
    "Change in self-reported pain levels in participants microdosing GLP1s",
    "Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s",
    "Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s",
    "Change in mood in participants microdosing GLP1s",
    "Change in heart rate variability in participants microdosing GLP1s",
    "Changes in sleep patterns in participants microdosing GLP1s",
    "Change in frequency of physical activity in participants microdosing GLP1s",
    "Change in frequency of physical activity in participants microdosing GLP1s"
   ],
   "in_automated_pull": true,
   "category": "named microdosing",
   "dose_tested": "compounded semaglutide 1 mg/mL, sublingual or injected; no dose stated",
   "note": "AgelessRx; randomized vs sublingual placebo; outcomes are pain, blood counts, metabolites, mood, HRV, sleep, activity"
  },
  {
   "nct": "NCT07325500",
   "title": "Incretin Microdosing for Cardiometabolic Health in People With HIV",
   "sponsor": "The University of Texas Health Science Center, Houston",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE2"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 30,
   "enrollment_type": "ESTIMATED",
   "status": "RECRUITING",
   "start": "2026-02-12",
   "primary_completion": "2028-05-31",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2026-01-08",
   "last_update": "2026-02-18",
   "results_posted": false,
   "primary_outcomes": [
    "Percent weight regain from weeks 12-60 (microdosing period)"
   ],
   "in_automated_pull": true,
   "category": "named microdosing",
   "dose_tested": "semaglutide 0.5 mg weekly after reaching 2 mg (Ozempic's lowest labeled maintenance dose)",
   "note": "UTHealth Houston; people with HIV; vs stopping; primary outcome weight regain weeks 12-60"
  },
  {
   "nct": "NCT07588984",
   "title": "GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study",
   "sponsor": "Noom Inc.",
   "study_type": "OBSERVATIONAL",
   "phases": null,
   "allocation": null,
   "enrollment": 2310,
   "enrollment_type": "ESTIMATED",
   "status": "NOT_YET_RECRUITING",
   "start": "2026-04-30",
   "primary_completion": "2029-05",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2026-05-15",
   "last_update": "2026-05-15",
   "results_posted": false,
   "primary_outcomes": [
    "Change in Body Weight",
    "Change in fasting glucose",
    "Change in HbA1c",
    "Change in LDL cholesterol",
    "Change in HDL cholesterol",
    "Change in total cholesterol",
    "Change in triglycerides",
    "Change in Body Composition",
    "GLP-1 Side Effect Profile"
   ],
   "in_automated_pull": true,
   "category": "named microdosing",
   "dose_tested": "compounded semaglutide or tirzepatide 'microdose' arms; no dose stated",
   "note": "Noom; observational cohort, not randomized"
  },
  {
   "nct": "NCT07832084",
   "title": "Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s",
   "sponsor": "Jing Luo",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE4"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 60,
   "enrollment_type": "ESTIMATED",
   "status": "NOT_YET_RECRUITING",
   "start": "2026-11-01",
   "primary_completion": "2027-04-30",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2026-09-21",
   "last_update": "2026-10-05",
   "results_posted": false,
   "primary_outcomes": [
    "Feasibility of recruitment and retention"
   ],
   "in_automated_pull": true,
   "category": "extended interval",
   "dose_tested": "taper to semaglutide 0.5 mg or tirzepatide 5 mg every other week",
   "note": "vs staying on full dose vs switching to phentermine-topiramate; primary outcome is feasibility"
  },
  {
   "nct": "NCT07574723",
   "title": "Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity",
   "sponsor": "Dasman Diabetes Institute",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "NA"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 68,
   "enrollment_type": "ESTIMATED",
   "status": "RECRUITING",
   "start": "2026-05-15",
   "primary_completion": "2029-05-15",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2026-05-08",
   "last_update": "2026-07-08",
   "results_posted": false,
   "primary_outcomes": [
    "Vomiting episodes per patient assessed using the Modified Index of Nausea, Vomiting, and Retching (M-INVR)"
   ],
   "in_automated_pull": true,
   "category": "click-based titration",
   "dose_tested": "tirzepatide, symptom-guided 'click-based' dose increases vs per-label escalation",
   "note": "Dasman Diabetes Institute, Kuwait; primary outcome vomiting episodes"
  },
  {
   "nct": "NCT06047548",
   "title": "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",
   "sponsor": "Eli Lilly and Company",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE3"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 441,
   "enrollment_type": "ACTUAL",
   "status": "COMPLETED",
   "start": "2023-09-20",
   "primary_completion": "2026-01-20",
   "primary_completion_type": "ACTUAL",
   "first_posted": "2023-09-21",
   "last_update": "2026-03-25",
   "results_posted": false,
   "primary_outcomes": [
    "Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period"
   ],
   "in_automated_pull": false,
   "category": "step-down maintenance",
   "dose_tested": "tirzepatide 5 mg vs maximum tolerated dose vs placebo after 60 weeks",
   "note": "SURMOUNT-MAINTAIN (Lilly); registry text does not use dose-lowering words, added by hand; results published in The Lancet, none posted on the registry"
  },
  {
   "nct": "NCT07294950",
   "title": "Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination",
   "sponsor": "Mount Sinai Hospital, Canada",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE3"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 98,
   "enrollment_type": "ESTIMATED",
   "status": "RECRUITING",
   "start": "2026-02-01",
   "primary_completion": "2028-09",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2025-12-19",
   "last_update": "2026-02-11",
   "results_posted": false,
   "primary_outcomes": [
    "Differences in changes in body weight between each study group"
   ],
   "in_automated_pull": true,
   "category": "taper to stop",
   "dose_tested": "semaglutide cut 25% every 4 weeks to zero vs abrupt stop",
   "note": "Mount Sinai Hospital, Canada"
  },
  {
   "nct": "NCT07783854",
   "title": "A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity",
   "sponsor": "Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE4"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 72,
   "enrollment_type": "ESTIMATED",
   "status": "NOT_YET_RECRUITING",
   "start": "2026-09-01",
   "primary_completion": "2027-12-30",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2026-08-25",
   "last_update": "2026-08-25",
   "results_posted": false,
   "primary_outcomes": [
    "Percentage change in body weight from baseline to week 24"
   ],
   "in_automated_pull": true,
   "category": "taper",
   "dose_tested": "semaglutide 1.7 mg cut 25% every 8 weeks vs staying on 1.7 mg",
   "note": "Union Hospital, Wuhan"
  },
  {
   "nct": "NCT07859176",
   "title": "Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery",
   "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE4"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 100,
   "enrollment_type": "ESTIMATED",
   "status": "NOT_YET_RECRUITING",
   "start": "2026-10",
   "primary_completion": "2028-04",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2026-10-05",
   "last_update": "2026-10-05",
   "results_posted": false,
   "primary_outcomes": [
    "Percentage change in body weight"
   ],
   "in_automated_pull": true,
   "category": "taper to stop",
   "dose_tested": "semaglutide 1.7, 1.0, 0.5, 0.25 mg for 4 weeks each vs placebo pens",
   "note": "after bariatric surgery, Egypt"
  },
  {
   "nct": "NCT07092618",
   "title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation",
   "sponsor": "AgelessRx",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE2",
    "PHASE3"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 150,
   "enrollment_type": "ESTIMATED",
   "status": "RECRUITING",
   "start": "2024-12-17",
   "primary_completion": "2025-08",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2025-07-30",
   "last_update": "2025-07-30",
   "results_posted": false,
   "primary_outcomes": [
    "Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent)",
    "Evaluate the effectiveness of metformin + rapamycin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
    "Evaluate the effectiveness of metformin + LDN in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)"
   ],
   "in_automated_pull": true,
   "category": "taper to stop",
   "dose_tested": "Wegovy down to 0.5 mg or Ozempic down to 0.25 mg over 3 months, then stop; plus metformin, rapamycin or low-dose naltrexone",
   "note": "AgelessRx; primary outcome weight 6 months after stopping"
  },
  {
   "nct": "NCT06449625",
   "title": "Semaglutide in Auto-HSCT",
   "sponsor": "Klaus Gottlob Müller",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE2"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 40,
   "enrollment_type": "ESTIMATED",
   "status": "NOT_YET_RECRUITING",
   "start": "2024-08-12",
   "primary_completion": "2026-12-31",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2024-06-10",
   "last_update": "2024-06-10",
   "results_posted": false,
   "primary_outcomes": [
    "gastrointestinal mucositis severity"
   ],
   "in_automated_pull": true,
   "category": "fixed low dose",
   "dose_tested": "semaglutide 0.25-0.5 mg weekly vs placebo",
   "note": "mouth sores during stem-cell transplant, Germany"
  },
  {
   "nct": "NCT07772960",
   "title": "Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes",
   "sponsor": "Yale University",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE1"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 90,
   "enrollment_type": "ESTIMATED",
   "status": "NOT_YET_RECRUITING",
   "start": "2026-10-01",
   "primary_completion": "2031-10-31",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2026-08-19",
   "last_update": "2026-08-19",
   "results_posted": false,
   "primary_outcomes": [
    "Alcohol use days"
   ],
   "in_automated_pull": true,
   "category": "fixed low dose",
   "dose_tested": "semaglutide 1.0 mg ('low dose') vs 2.0 mg vs placebo",
   "note": "Yale; alcohol use"
  },
  {
   "nct": "NCT06896981",
   "title": "Semaglutide in Women With Polycystic Ovary Syndrome and Obesity",
   "sponsor": "Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE2",
    "PHASE3"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 31,
   "enrollment_type": "ACTUAL",
   "status": "COMPLETED",
   "start": "2025-01-01",
   "primary_completion": "2025-10-31",
   "primary_completion_type": "ACTUAL",
   "first_posted": "2025-03-26",
   "last_update": "2026-10-07",
   "results_posted": false,
   "primary_outcomes": [
    "Weight",
    "Body mass index",
    "Waist circumference",
    "Hip circumference",
    "Blood pressure",
    "Acanthosis nigricans",
    "Fasting plasma glucose",
    "Fasting insulin",
    "Homeostasis model assessment of insulin resistance",
    "Total cholesterol",
    "HDL-cholesterol",
    "LDL-cholesterol",
    "Triglyceride"
   ],
   "in_automated_pull": true,
   "category": "fixed low dose",
   "dose_tested": "semaglutide 0.5 mg ('low-dose') plus metformin vs metformin",
   "note": "PCOS, Bangladesh; local non-originator semaglutide"
  },
  {
   "nct": "NCT02909933",
   "title": "Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity",
   "sponsor": "University Medical Centre Ljubljana",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE4"
   ],
   "allocation": "RANDOMIZED",
   "enrollment": 30,
   "enrollment_type": "ACTUAL",
   "status": "COMPLETED",
   "start": "2015-07",
   "primary_completion": "2015-10",
   "primary_completion_type": "ACTUAL",
   "first_posted": "2016-09-21",
   "last_update": "2016-09-21",
   "results_posted": false,
   "primary_outcomes": [
    "The main outcome was change in body weight."
   ],
   "in_automated_pull": true,
   "category": "fixed low dose",
   "dose_tested": "liraglutide 1.2 mg plus metformin vs liraglutide 3 mg",
   "note": "PCOS, Ljubljana; completed 2015"
  },
  {
   "nct": "NCT07513168",
   "title": "Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults",
   "sponsor": "Asian Institute Of Medical Sciences",
   "study_type": "INTERVENTIONAL",
   "phases": [
    "PHASE4"
   ],
   "allocation": "NA",
   "enrollment": 60,
   "enrollment_type": "ESTIMATED",
   "status": "RECRUITING",
   "start": "2025-08-01",
   "primary_completion": "2026-08-30",
   "primary_completion_type": "ESTIMATED",
   "first_posted": "2026-04-06",
   "last_update": "2026-04-06",
   "results_posted": false,
   "primary_outcomes": [
    "Percentage Change in Body Weight"
   ],
   "in_automated_pull": true,
   "category": "fixed low dose",
   "dose_tested": "'low-dose' locally available semaglutide; dose not stated",
   "note": "single arm, Pakistan"
  }
 ],
 "labels": [
  {
   "drug": "Ozempic (semaglutide injection)",
   "spl_version": 20,
   "start": "0.25 mg weekly for 4 weeks",
   "lowest_maintenance": "0.5 mg weekly",
   "starter_dose_language": "start dose is to reduce GI risk; maintenance 0.5, 1 or 2 mg"
  },
  {
   "drug": "Wegovy (semaglutide injection)",
   "spl_version": 19,
   "start": "0.25 mg weekly",
   "lowest_maintenance": "1.7 mg weekly",
   "starter_dose_language": "maintenance 1.7 or 2.4 mg; 2 or more missed doses means restarting escalation"
  },
  {
   "drug": "Rybelsus (oral semaglutide)",
   "spl_version": 14,
   "start": "3 mg daily",
   "lowest_maintenance": "7 mg daily",
   "starter_dose_language": "starting dose 'is not effective for glycemic control'"
  },
  {
   "drug": "Zepbound (tirzepatide)",
   "spl_version": 40,
   "start": "2.5 mg weekly",
   "lowest_maintenance": "5 mg weekly",
   "starter_dose_language": "'The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage'; 'consider a lower maintenance dosage' if not tolerated"
  },
  {
   "drug": "Mounjaro (tirzepatide)",
   "spl_version": 40,
   "start": "2.5 mg weekly",
   "lowest_maintenance": "label raises in 2.5 mg steps 'if additional glycemic control is needed'",
   "starter_dose_language": "no starter-only statement"
  },
  {
   "drug": "Saxenda (liraglutide)",
   "spl_version": 22,
   "start": "0.6 mg daily",
   "lowest_maintenance": "3 mg daily",
   "starter_dose_language": "'lower dosages are for titration only'; stop if 3 mg not tolerated"
  },
  {
   "drug": "Victoza (liraglutide)",
   "spl_version": 31,
   "start": "0.6 mg daily",
   "lowest_maintenance": "1.2 mg daily",
   "starter_dose_language": "0.6 mg 'is not effective for glycemic control in adults'"
  },
  {
   "drug": "Trulicity (dulaglutide)",
   "spl_version": 62,
   "start": "0.75 mg weekly",
   "lowest_maintenance": "0.75 mg weekly",
   "starter_dose_language": "starting dose can be kept"
  },
  {
   "drug": "Foundayo (orforglipron)",
   "spl_version": 10,
   "start": "0.8 mg daily",
   "lowest_maintenance": "per label escalation",
   "starter_dose_language": "starting dose is part of escalation"
  }
 ],
 "pubmed": {
  "query": "microdos*[tiab] AND (semaglutide[tiab] OR tirzepatide[tiab] OR GLP-1[tiab] OR GLP-1RA[tiab] OR incretin[tiab] OR liraglutide[tiab])",
  "searched": "2026-10-20",
  "records": 13,
  "about_glp1_microdosing_practice": 9,
  "randomized_trials": 0,
  "pmids_on_topic": [
   "42892786",
   "42571951",
   "42244165",
   "40540673",
   "39808463",
   "42788826",
   "42668762",
   "42201545",
   "42857675"
  ]
 }
}